Biogen Inc. and Ionis Pharmaceuticals Inc. have strengthened their ongoing relationship with a third deal built around antisense technology that Isis has been advancing for two decades. The deal gives Biogen further insight into the technology’s versatility, and is another step in Isis’ long road to validating claims that antisense is a broad-based drug discovery platform that can produce marketable drugs across multiple therapeutic areas.
The companies announced their third collaboration this year on Dec. 10, this time involving the earliest stage work that the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?